WuXi Biologics Named to 2026 Forbes China ESG 50 List
News related to:WuXi Biologics · 3 min read
SHANGHAI, Sept. 16, 2026 /CourierPR/ -- WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has been named to the 2026 Forbes China ESG 50 list for its outstanding performance in sustainable development, Green CRDMO solutions, and ESG digital innovation. The company was highlighted as one of the representative companies in ESG data governance, reflecting its commitment to creating environmental and social value through innovative technologies and operational excellence.
The 2026 Forbes China ESG 50 list, which started with an initial candidate pool of Chinese companies included in the Forbes Global 2000, selected 50 companies with exceptional ESG performance and leading practices. This year's list focuses on three core themes: enhanced disclosure granularity, advanced compliance strategies, and the use of technology tools, including AI. WuXi Biologics was recognized for its comprehensive ESG data governance system, which covers its global operations. The company achieved a 30% reduction in Scope 1 and Scope 2 greenhouse gas emission intensity compared to 2020, and reduced water intensity by 32% compared to 2019, exceeding its original 30% target.
WuXi Biologics has embedded sustainable development into its corporate strategy, guided by the Green CRDMO strategy. The company is committed to creating environmental and social value through innovative technologies and operational excellence, empowering global partners to advance their own sustainability goals. WuXi Biologics integrates ESG principles into biologics research, development, manufacturing, supply chain management, and global business operations, contributing to the green transformation of the biopharmaceutical industry.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of the ESG Committee, stated, "WuXi Biologics' inclusion in the 2026 Forbes China ESG 50 list is a recognition of the company's long-standing commitment to sustainable development, deepening Green CRDMO practices, and ESG digital innovation. Sustainability has been deeply embedded in our corporate strategy and global operations. Green CRDMO is not only our long-term commitment but also an important pathway to empowering client growth and unlocking green business value."
To support strategic execution, WuXi Biologics has established a four-tier ESG governance structure, comprising the ESG Committee, made up of Board members to provide oversight; the ESG Steering Group, composed of senior management to offer key insights; a dedicated ESG function to drive implementation; and issue-specific task forces to advance actions across key topics. This structure forms a closed-loop management mechanism from strategic decision-making and target management to execution feedback. The company aligns with the United Nations Sustainable Development Goals (UN SDGs) and fosters systematic management across topics such as healthcare access, technology innovation, product quality, climate change, responsible manufacturing, employee development, business ethics, and a sustainable supply chain.
WuXi Biologics translates strategic requirements into concrete Green CRDMO practices that span biologics research, development, manufacturing, and global business operations. The company uses innovative technologies, process optimization, and green operations to integrate environmental performance improvement, operational efficiency, and customer value creation. WuXi Biologics' WuXiBody™ bispecific antibody platform enhances molecular developability and stability while reducing environmental impact by shortening R&D cycles and lowering the natural resources and energy required to maintain development conditions.
In green development and manufacturing, the WuXiUI™ ultra-intensified fed-batch production technology platform can improve production efficiency by 3-8 times and reduce life-cycle environmental impact by up to 60% compared to traditional fed-batch processes. The company also leverages the advantages of single-use technology for biologics manufacturing, which can save up to 70% of water consumption, reduce resource consumption by approximately 33%, and lower the negative impact on climate change by approximately 40% compared to traditional stainless-steel processes. The combination of WuXiUI™ and single-use technology can reduce the product carbon footprint by up to 80%, accelerating the transition of green manufacturing from concept to scalable practice.
WuXi Biologics advances carbon reduction, water conservation, and waste reduction through lean management in green operations. The company shares 242 outstanding energy-saving cases through its WuXi Biologics Green CRDMO White Paper to promote the replication of green operations practices across global sites and the broader industry value chain.
WuXi Biologics has received international recognition for its sustainable development performance, including the highest MSCI AAA ESG Rating, the EcoVadis Platinum Medal, and inclusion in the Dow Jones Best-in-Class World Index and Best-in-Class Emerging Markets Index. These recognitions reflect the company's continued progress across environmental, social, and governance dimensions, as well as global stakeholders' acknowledgment of WuXi Biologics' sustainability strategy, governance capabilities, and practical achievements.